Effect of miR-200c on proliferation, invasion and apoptosis of prostate cancer LNCaP cells

Lin,Jianxi; Lu,Yi; Zhang,Xiao; Mo,Qiwang; Yu,Ling

doi:10.3892/ol.2019.10102

Effect of miR-200c on proliferation, invasion and apoptosis of prostate cancer LNCaP cells

Authors:
- Jianxi Lin
- Yi Lu
- Xiao Zhang
- Qiwang Mo
- Ling Yu
View Affiliations

Affiliations: Shengzhou People's Hospital, Shengzhou, Zhejiang 312400, P.R. China
Published online on: March 4, 2019 https://doi.org/10.3892/ol.2019.10102
Pages: 4299-4304
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of miRNA‑200c (miR‑200c) on the proliferation, invasion and apoptosis of prostate cancer cell line LNCaP was investigated. The difference in miR‑200c expression was observed using RT‑qPCR in the NC group (transfected empty plasmid), simulation group (simulation sequence) and inhibition group (transferred inhibition sequence), which were established by transfecting LNCaP cells with a kit. The proliferation, invasion and apoptosis of cells after transfection were detected using the cell counting kit‑8 (CCK‑8) method, Transwell chamber and flow cytometry. RT‑qPCR detection showed that the relative expression of miR‑200c in LNCaP cells significantly increased compared with RWPE‑1 cells (P<0.05). The difference was statistically significant in the relative expression of miR‑200c cells among NC group, simulation group and inhibition group after transfection (P<0.05) and they significantly decreased in NC group of cells compared with the simulation group (P<0.05). CCK‑8 detection showed that there were differences at the 2nd, 3rd, 4th and 5th days of growth in the NC group, simulation group and inhibition group of cells (P<0.05) and there was a difference in the proliferation ability between NC group and simulation group (P<0.05). Transwell chamber detection showed that there was a difference in the invasion ability among NC group, simulation group and inhibition group of cells (P<0.05), among which the number of passed membrane cells in inhibition group was significantly smaller than that in NC group and simulation group (P<0.05), and the difference was not statistically significant between NC group and simulation group (P>0.05). Flow cytometry detection of the apoptosis ability of each group of cells showed that there was a difference in the apoptotic rate in the NC, simulation and inhibition groups (P<0.05). The low expression of miR‑200c is beneficial to inhibit the proliferation and invasion of LNCaP cells in vitro and to promote apoptosis, which may be a potential target for prostate cancer biotherapy.

View Figures

View References

1	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, et al ERSPC Investigators, : Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384:2027–2035. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries. Eur Urol. 70:862–874. 2016. View Article : Google Scholar : PubMed/NCBI
4	Stewart BW and Wild CP: World Cancer Report 2014. IARC Publications. (Lyon). 2014.
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
6	Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
7	Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S and Visakorpi T: The molecular evolution of castration-resistant prostate cancer. Eur Urol Focus. 2:506–513. 2016. View Article : Google Scholar : PubMed/NCBI
8	Nelson WG, De Marzo AM and Isaacs WB: Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar : PubMed/NCBI
9	Bandara KV, Michael MZ and Gleadle JM: MicroRNA biogenesis in hypoxia. MicroRNA. 6:80–96. 2017. View Article : Google Scholar : PubMed/NCBI
10	Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai FJ and Chen WC: E-cadherin gene 3-UTR C/T polymorphism is associated with prostate cancer. Urol Int. 75:350–353. 2005. View Article : Google Scholar : PubMed/NCBI
11	Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S: MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
12	Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP and Afshar-Oromieh A: Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 43:70–83. 2016. View Article : Google Scholar : PubMed/NCBI
15	Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, et al ICGC Prostate Group, : The evolutionary history of lethal metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
16	Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol. 197:S200–S207. 2017. View Article : Google Scholar : PubMed/NCBI
17	Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O and Ward EM: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 314:2054–2061. 2015. View Article : Google Scholar : PubMed/NCBI
18	Abd-Alazeez M, Ahmed HU, Arya M, Charman SC, Anastasiadis E, Freeman A, Emberton M and Kirkham A: The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level - can it rule out clinically significant prostate cancer? Urol Oncol. 32:45.e17–45.e22. 2014. View Article : Google Scholar
19	Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja H, Laurell T and Maeda M: A highly sensitive porous silicon (P-Si)-based human kallikrein 2 (hK2) immunoassay platform toward accurate diagnosis of prostate cancer. Sensors (Basel). 15:11972–11987. 2015. View Article : Google Scholar : PubMed/NCBI
20	Suzuki HI, Young RA and Sharp PA: Super-enhancer-mediated RNA processing revealed by integrative MicroRNA network analysis. Cell. 168:1000–1014.e15. 2017. View Article : Google Scholar : PubMed/NCBI
21	Li XL, Andersen JB, Ezelle HJ, Wilson GM and Hassel BA: Post-transcriptional regulation of RNase-L expression is mediated by the 3-untranslated region of its mRNA. J Biol Chem. 282:7950–7960. 2007. View Article : Google Scholar : PubMed/NCBI
22	Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
23	Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
24	Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
25	Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, Stampfer MR and Futscher BW: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
26	Tao T, Liu D, Liu C, Xu B, Chen S, Yin Y, Ang L, Huang Y, Zhang X and Chen M: Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development. Biochim Biophys Acta. 1839:858–865. 2014. View Article : Google Scholar : PubMed/NCBI
27	Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI
28	Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI